In a groundbreaking mid-stage clinical study conducted in China, Innovent Biologics Inc.’s pioneering obesity drug, mazdutide, has showcased remarkable and sustained efficacy in weight reduction over a 48-week period, resulting in an average weight loss of 18.6% of participants’ body weight.
Developed in collaboration with Eli Lilly & Co., mazdutide has proven to be a promising solution for combating obesity. The study’s success marks a significant milestone, as it paves the way for the drug’s progression into a late-stage clinical trial, scheduled to commence before the year’s end, according to a statement released by Innovent.
Notably, participants in the trial initially experienced an average weight loss of 15% of their body weight, equivalent to 14.7 kilograms (32.4 pounds), after 24 weeks of treatment, as reported in findings unveiled in May. Encouragingly, those who continued the regimen by maintaining a weekly dosage of 9 milligrams for an additional 24 weeks witnessed an impressive 19% reduction in their body weight, averaging 17.8 kilograms.
The sustained efficacy of mazdutide throughout this extended 48-week trial holds significant promise for the future of obesity treatment. With these encouraging results, Innovent and Eli Lilly are poised to advance into the final stages of clinical evaluation for mazdutide, with the goal of offering a groundbreaking solution to the global health challenge of obesity.
